More on BIIB
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $219.05 |
|
|||
| Open | $219.05 | ||||
| 52 Wk High | $333.65 | ||||
| 52 Wk Low | $223.02 | ||||
| Day High | $220.17 | ||||
| Day Low | $217.00 | ||||
| P/E | 27.93 | ||||
| EPS | $7.81 | ||||
| Volume | 176,106 | ||||
- Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
- Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-M
- Biogen (BIIB) Reiterated at Buy by Stifel After Investor Meeting
- Biogen (BIIB) PT Raised to $175 at HSBC
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
- Stoke, Biogen share 4-year data on zorevunersen for Dravet syndrome
- Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16t
- Biogen (BIIB) PT Raised to $245 at Piper Sandler
- Stoke, Biogen to present 4-year zorevunersen data at epilepsy congress
- Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Cong
Entities mentioned with biib
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
